Evidence map›Paper›PMID 30820806›Full record

ArticleFrontiers of medicine2019

Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl

Ruoxi Zhang, Jing Chen, Diangang Liu, Yu Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Frontiers of medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Role of liver sinusoidal endothelial cells in liver diseases.Nature reviews. Gastroenterology & hepatology · 2021
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ruoxi ZhangDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
Jing ChenDepartment of Gastroenterology, the Second Affiliated Hospital of Harbin Medical University, Harbin, 150010, China.
Diangang LiuDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China. liudiangang01@gmail.com.
Yu WangDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
Capital Medical University · CNHarbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increased serum urotensin II (UII) levels in human cirrhotic populations have been recently shown, but the long-term effects of UII receptor antagonist on the cirrhosis have not been investigated. To investigate the therapeutic effects of urotensin II receptor (UT) antagonist palosuran on rats with carbon tetrachloride (CCl

Indexed as

Portal PressureAnimalsCarbon TetrachlorideHemodynamicsHepatic Stellate CellsLiverLiver CirrhosisMaleNitric Oxide Synthase Type IIIQuinolinesRatsRats, Sprague-DawleyReceptors, G-Protein-Coupledrho-Associated KinasesTissue Inhibitor of Metalloproteinase-1Urea1-(2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)ureaCarbon TetrachlorideNitric Oxide Synthase Type IIINos3 protein, ratQuinolinesReceptors, G-Protein-Coupledrho-Associated KinasesTIMP1 protein, ratTissue Inhibitor of Metalloproteinase-1UreaUts2r protein, ratcirrhosishepatic stellate cellpalosuranportal hypertensionurotensin II

Identifiers

PMID30820806
OpenAlexW2918820017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.